Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeff P Sharman

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
Blood|March 2, 2026
Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trialJeff P Sharman, Luca Laurenti, Emmanuelle France Ferrant, et al.
Blood Advances|October 26, 2022
Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphomaAnas Younes, John M Burke, Bruce D Cheson, et al.
Blood Advances|January 4, 2018
Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphomaSven de Vos, Nina D Wagner-Johnston, Steven E Coutre, et al.
Leukemia & Lymphoma|October 3, 2018
Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER studyJeff P Sharman, Andres Forero-Torres, Luciano J Costa, et al.
Blood Advances|September 30, 2024
OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCLYuliya Linhares, Cesar O Freytes, Mohamad Cherry, et al.
Science Immunology|June 7, 2020
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19Mark Roschewski, Michail S Lionakis, Jeff P Sharman, et al.
The Lancet. Haematology|February 25, 2021
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trialJeff P Sharman, Danielle M Brander, Anthony R Mato, et al.
The Lancet. Oncology|February 1, 2017
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trialAndrew D Zelenetz, Jacqueline C Barrientos, Jennifer R Brown, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 25, 2026
Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6David Andorsky, Adelba Torres Lopez, Rakhee Vaidya, et al.
The Lancet. Oncology|December 17, 2013
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trialSusan O'Brien, Richard R Furman, Steven E Coutre, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
Blood|March 2, 2026
Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trialJeff P Sharman, Luca Laurenti, Emmanuelle France Ferrant, et al.
Blood Advances|October 26, 2022
Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphomaAnas Younes, John M Burke, Bruce D Cheson, et al.
Blood Advances|January 4, 2018
Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphomaSven de Vos, Nina D Wagner-Johnston, Steven E Coutre, et al.
Leukemia & Lymphoma|October 3, 2018
Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER studyJeff P Sharman, Andres Forero-Torres, Luciano J Costa, et al.
Blood Advances|September 30, 2024
OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCLYuliya Linhares, Cesar O Freytes, Mohamad Cherry, et al.
Science Immunology|June 7, 2020
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19Mark Roschewski, Michail S Lionakis, Jeff P Sharman, et al.
The Lancet. Haematology|February 25, 2021
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trialJeff P Sharman, Danielle M Brander, Anthony R Mato, et al.
The Lancet. Oncology|February 1, 2017
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trialAndrew D Zelenetz, Jacqueline C Barrientos, Jennifer R Brown, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 25, 2026
Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6David Andorsky, Adelba Torres Lopez, Rakhee Vaidya, et al.
The Lancet. Oncology|December 17, 2013
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trialSusan O'Brien, Richard R Furman, Steven E Coutre, et al.
Pageof 8